Press release
Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight
Key Takeaways from the Primary Sclerosing Cholangitis Market Report
* The increase in Primary Sclerosing Cholangitis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Primary Sclerosing Cholangitis Market is anticipated to witness growth at a considerable CAGR.
* The leading Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Promising Primary Sclerosing Cholangitis Therapies in the various stages of development include Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
* April 2024:- Pliant Therapeutics Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC). A Phase 2a, multicenter, randomized, double-blind, dose-ranging, placebo-controlled, study to evaluate the safety, tolerability, and PK of PLN-74809 in participants with primary sclerosing cholangitis and suspected liver fibrosis.
* April 2024:-Mirum Pharmaceuticals Inc.- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
Discover which therapies are expected to grab the Primary Sclerosing Cholangitis Market Share @ Primary Sclerosing Cholangitis Market Outlook [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. Bile ducts are the tubes that carry bile (a digestive fluid produced by the liver) from the liver to the gallbladder and small intestine. In PSC, inflammation and scarring narrow and block the bile ducts, leading to problems with bile flow and causing damage to the liver over time.
Primary Sclerosing Cholangitis Epidemiology Insights
The epidemiology section of Primary Sclerosing Cholangitis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Primary Sclerosing Cholangitis Epidemiology trends @ Primary Sclerosing Cholangitis Epidemiological Insights [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Sclerosing Cholangitis Drugs Market
The Primary Sclerosing Cholangitis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Primary Sclerosing Cholangitis signaling in Primary Sclerosing Cholangitis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Primary Sclerosing Cholangitis Treatment Market Landscape
The Primary Sclerosing Cholangitis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Primary Sclerosing Cholangitis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Primary Sclerosing Cholangitis treatment guidelines, visit @ Primary Sclerosing Cholangitis Treatment Market Landscape [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Primary Sclerosing Cholangitis Market Outlook
The report's outlook on the Primary Sclerosing Cholangitis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Primary Sclerosing Cholangitis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Primary Sclerosing Cholangitis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Primary Sclerosing Cholangitis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Primary Sclerosing Cholangitis Drugs Uptake
The drug chapter of the Primary Sclerosing Cholangitis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Primary Sclerosing Cholangitis.
Major Primary Sclerosing Cholangitis Companies
Several Primary Sclerosing Cholangitis Companies working in the market include Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
Learn more about the FDA-approved drugs for Primary Sclerosing Cholangitis @ Drugs for Primary Sclerosing Cholangitis Treatment [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Primary Sclerosing Cholangitis Market Research Report
* Coverage- 7MM
* Primary Sclerosing Cholangitis Companies- Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, and others.
* Primary Sclerosing Cholangitis Pipeline Therapies- Ritivixibat, Cenicriviroc 150 mg, HK-660S, Elafibranor 80 mg, Volixibat, PLN-74809, and others.
* Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis Market Drivers and Barriers
* Primary Sclerosing Cholangitis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Primary Sclerosing Cholangitis Drugs in development @ Primary Sclerosing Cholangitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Primary Sclerosing Cholangitis (PSC) Market Overview at a Glance
4. Executive Summary of Primary Sclerosing Cholangitis (PSC)
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Emerging Therapies
10. Primary Sclerosing Cholangitis (PSC): Seven Major Markets + Nordic Countries Market Analysis
11. SWOT Analysis
12. Unmet Needs
13. KOL Views
14. Market Access and Reimbursement
15. Acronyms and Abbreviations
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-market-to-exhibit-growth-at-a-cagr-of-x-by-2032-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Market to Exhibit Growth at a CAGR of X% by 2032, estimates DelveInsight here
News-ID: 3475573 • Views: …
More Releases from ABNewswire
Blurring the Lines: Fiorenzo Bernasconi's Artistic Leap Through Specular Interse …
A Revolutionary Blend of Art Forms: Fiorenzo Bernasconi's latest album, "Intersezioni," (Musica Presente Records) showcases a unique fusion of poetry and music, transcending traditional artistic boundaries through his Specular Intersectionism method. This approach not only merges different artistic disciplines but also invites listeners to experience music and poetry as intertwined reflections of each other, offering a fresh perspective in the world of contemporary classical music.
In the constantly evolving world of…
Schneider Electric says Chinese market remains important
Schneider Electric has established R & D centers in multiple Chinese cities including Beijing, Shanghai, Wuxi, Xi'an and Shenzhen.
HANNOVER, Germany - May 4, 2024 - A senior executive of Schneider Electric said that the Chinese market remains important, a fact that "has not changed."
Barbara Frei, the company's executive vice president, made the remarks during an interview with Xinhua at the ongoing Hannover Messe 2024 Trade Fair.
"The importance of the Chinese…
Schneider Electric Boosts Industrial Competitiveness
Schneider Electric is said to showcase the latest innovations in its portfolio, including industrial software, Artificial Intelligence and Digital Twin technology. These solutions will be demonstrated through the lens of a digital and sustainable life science campus, highlighting Schneider's deep domain expertise across the entire industrial value chain.
"With industry contributing around 45% of global greenhouse gas emissions, it is clear we must act to reduce this and support industrial decarbonization…
Essential Guide to Residential Electrical Repair
From addressing minor issues like flickering lights to more complex tasks such as rewiring circuits, residential electrical repair encompasses a wide range of services aimed at maintaining the integrity of the electrical infrastructure.
Residential electrical repair is a critical aspect of homeownership, ensuring the safety, functionality, and efficiency of electrical systems within the home. From addressing minor issues like flickering lights to more complex tasks such as rewiring circuits, residential electrical…
More Releases for Primary
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps…
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025: …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary…
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market.
Description
The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries".
The Global Primary Cells…
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market.
These companies have been…
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
